Paget's Disease Treatment Market By Type Of Drug Class (Bisphosphonates, Calcitonin Analogues (Salmon Calcitonin), Analgesics, Calcium & Vitamin D Supplements) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Industry Outlook

The Paget's disease treatment market is projected to grow at a CAGR of 3.4% during the forecast period from 2019 to 2027. Paget's disease of bone affects the way that bone is renewed and repaired; during this process, an uncontrolled level of bone generation occurs, which results in abnormal bone formation. The affected bone is weaker than normal and leads to a bend or deformity, making that bone fragile. According to Arthritis Research UK, Paget's disease is identified as the most common disease in the UK and is also observed in people from southern and western Europe, as well as other countries such as Australia and New Zealand. In addition to that, around 2 to 3 people in 100 and older have Paget's disease.

Market Synopsis

Bisphosphonate is the most preferred drug class against Paget's disease and will maintain its dominance throughout the forecast period. In 2018, bisphosphonates were identified as the largest segment, being the first choice of medical practitioners and increasing awareness related to Paget's disease. Bisphosphonates are a vital class of drugs that tackle Paget's disease by decreasing the destruction of abnormal osteoclastic bone. In addition, bisphosphonates usually get settled in the bone; the advantage may last for several months or years and, if given in the early stages, may prevent further complications.

Europe is the fastest-growing market due to rising awareness of Paget's disease among medical practitioners and increasing diagnostic rates.

During the forecast period from 2019 to 2027, Europe is expected to be the fastest-growing Paget's disease treatment market, specifically due to increasing awareness among medical practitioners related to rare disorders and a developed healthcare infrastructure that is supporting the rise in diagnosis rates. According to market experts, the rising geriatric population in the U.K. and its highest prevalence rate of 4.6% make it the most prevalent country globally. Thus, in the near future, Europe is expected to surpass North America and dominate the market during the forecast period from 2019 to 2027.

Periods of History and Forecast

The Paget's disease treatment market was analyzed along with current market trends for the base year of 2018, and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report covers the elaborative study of Paget's disease treatment market, covering market understandings and assumptions studied based on exhaustive qualitative and quantitative data collected through primary and secondary research. Through primary interviews, industry sponsors studied and comprehended market dynamics such as opportunities, drivers, and challenges, which were further segmented by region and country. This report also includes an in-depth study of multiple segments of global Paget's disease treatment, such as the type of drug class and geography. The report also provides insight into the competitive analysis of the key companies operating in Paget's disease treatment market, including detailed information such as current and future business strategies, financial data, and product portfolios.

The major companies currently available in the market were analyzed based on recent market updates, product portfolios, financial data, and key strategies. This report also includes an attractive investment proposition studied with the help of PESTEL analysis, which focuses on in-depth geographical research. Key companies present in the overall report are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Neopharma, Inc., Sanofi S.A., Allergan, Fresenius Kabi, Sun Pharmaceutical Industries Ltd., and Mallinckrodt Pharmaceuticals, among others.

Key questions are answered in this report.

  • Which drug class is in high demand to treat Paget's disease, and why?
  • What are the present market strategies and policies studied and applied by major market players and the competitive landscape of the global Paget's disease treatment market?
  • Which are the important and imminent geographical markets (regions and countries) in Paget's disease treatment market, and why?
  • Which is the largest and fastest-growing region globally in the Paget's disease treatment market?
  • What will be the expected sales of drugs under development in Paget's disease treatment market?

 Frequently Asked Questions:

The market for Paget's Disease Treatment Market is expected to reach in XX Bn in 2027.

The Paget's Disease Treatment Market is expected to see significant CAGR growth over the coming years, at 3.4%.

The report is forecasted to 2019-2027.

The base year of this report is 2018.

Novartis AG, Merck & Co., Inc.,Neopharma, Inc., Sanofi SA,Allergan Pharmaceuticals International Ltd., are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Jun 2019
Category:  Pharmaceuticals
Report ID:   59734
Report Format:   PDF
Pages:   120
Rating:    4.5 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support